Carmen Halabi, M.D., Ph.D.  chalabi@wustl.edu

Instructor in Pediatrics, Nephrology
Nephrology

phone: (314) 286-1574

Clinical Interests

My clinical interests include diagnosis and management of congenital anomalies of the kidney and urinary tract, chronic kidney disease, hypertension, kidney stones, urinary tract infections, glomerular diseases including nephrotic and nephritic syndromes, and electrolyte disorders. In the acute setting, as part of the dialysis and pheresis team, we provide all modalities of renal replacement therapies and therapeutic plasma exchange.

Education

  • BS, Honors and High Distinction, The University of Iowa2001
  • PhD, The University of Iowa2009
  • MD, The University of Iowa Carver College of Medicine2009

Training

  • Resident in Pediatrics, Saint Louis Children's Hospital2009 - 2011
  • Fellow in Pediatric Nephrology, Washington University School of Medicine2011 - 2015

Licensure and Board Certification

  • MO, State Board of Registration for the Healing Arts - Physician and Surgeon 2012
  • American Board of Pediatrics/General Pediatrics 2012
  • IL, Department of Financial and Professional Regulation - Licensed Physician and Surgeon 2015
  • The American Board of Pediatrics/Pediatric Nephrology 2016

Honors

  • Predoctoral Training Program in Genetics, National Institutes of Health, 5T32GM008629, PI: Jeffrey Murray, M.D.2005 - 2007
  • Caroline tum Suden/Frances A. Hellebrandt Professional Opportunity Award, American Physiological Society2007
  • Research Day Award for Best Graduate Student Basic Science Poster, Department of Internal Medicine, The University of Iowa Carver College of Medicine2007
  • Research Week Poster Award, THe University of Iowa Carver College of Medicine2007
  • Merck New Investigator Award, American Heart Association - Council on High Blood Pressure2007
  • Best Poster Presentation Award, The University of Iowa Genetics Ph.D. Program2007
  • Dean's Distinguished Dissertation Award, The University of Iowa2010
  • Postdoctoral Developmental Cardiology and Pulmonary Training Program, National Institutes of Health, 5T32HL007873, PI: Robert Mecham, Ph.D.2012 - 2014
  • Trainee Research Award in Pediatric Nephrology, American Society of Pediatric Nephrology2014
  • Physician Scientist Training Program, National Institutes of Health, 2T32HD043010, PI: Alan Schwartz, Ph.D., M.D.2014 - 2015
  • Pediatric Physician-Scientist Training Program Fellowship Support, Mallinckrodt Foundation2014 - 2015
  • Travel Award, American Society for Matrix Biology2014
  • "Teresa Vietti Fellow" Award, Department of Pediatrics, Washington University School of Medicine2015
  • Scholar of the Child Health Research Center at Washington University School of Medicine, National Institutes of Health, K12-HD0762242015 - 2017

Recent Publications view all (14)


Publication Co-Authors

  1. Fibulin-4 is essential for maintaining arterial wall integrity in conduit but not muscular arteries. Sci Adv. 2017;3(5):e1602532. PMCID:PMC5415335  PMID:28508064 
  2. In tandem extracorporeal therapies during hemodialysis in pediatric patients. Hemodial Int. 2016;20 Suppl 1:S40-S43. PMID:27669548 
  3. Loss of function mutation in LOX causes thoracic aortic aneurysm and dissection in humans. Proc Natl Acad Sci U S A. 2016;113(31):8759-64. PMID:27432961 
  4. Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness. Am J Physiol Heart Circ Physiol. 2015;309(5):H1008-16. doi:10.1152/ajpheart.00288.2015  PMID:26232234 
  5. Fibulin-4 E57K Knock-in Mice Recapitulate Cutaneous, Vascular and Skeletal Defects of Recessive Cutis Laxa 1B with both Elastic Fiber and Collagen Fibril Abnormalities. J Biol Chem. 2015;290(35):21443-59. doi:10.1074/jbc.M115.640425  PMID:26178373 
  6. Aggressive blood pressure control for chronic kidney disease unmasks moyamoya! Clin Kidney J. 2013;6(5):495-9. doi:10.1093/ckj/sft090  PMCID:PMC4438405  PMID:26064513 
  7. Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta. Arterioscler Thromb Vasc Biol. 2010;30(3):518-25. doi:10.1161/ATVBAHA.109.200733  PMCID:PMC2850258  PMID:20018933 
  8. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res. 2010;106(2):373-82. doi:10.1161/CIRCRESAHA.109.208645  PMCID:PMC2818798  PMID:19926873 
  9. Germ line activation of the Tie2 and SMMHC promoters causes noncell-specific deletion of floxed alleles. Physiol Genomics. 2008;35(1):1-4. doi:10.1152/physiolgenomics.90284.2008  PMCID:PMC2574738  PMID:18612081 
  10. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res. 2008;103(6):654-61. doi:10.1161/CIRCRESAHA.108.176339  PMCID:PMC2583077  PMID:18676352 
  11. Interference with PPARgamma signaling causes cerebral vascular dysfunction, hypertrophy, and remodeling. Hypertension. 2008;51(4):867-71. doi:10.1161/HYPERTENSIONAHA.107.103648  PMCID:PMC2408877  PMID:18285614 
  12. Interference with PPAR gamma function in smooth muscle causes vascular dysfunction and hypertension. Cell Metab. 2008;7(3):215-26. doi:10.1016/j.cmet.2007.12.008  PMCID:PMC2275166  PMID:18316027 
  13. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol. 2007;81(2):813-21. doi:10.1128/JVI.02012-06  PMCID:PMC1797474  PMID:17079315 
  14. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications. Am J Cardiovasc Drugs. 2005;5(6):389-98. PMID:16259527 
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130